• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation & lt;48 h duration: results of an EHRA survey
AbstractData supporting the safety of cardioversion (CV) of atrial fibrillation (AF) without anticoagulation in patients with AF duration<48  h are scarce. Observational studies suggest that the risk of stroke in these patients is very low when the definite duration of the AF episode is of<48  h and the clinical risk profile as estimated through the CHA2DS2VASc score is low (a score of 0 for men and 1 for women). As the recent 2020 European Society of Cardiology (ESC) guidelines indication for this clinical scenario is based mainly on consensus, we sent out a survey to assess the current clinical practice on anti...
Source: Europace - May 15, 2021 Category: Cardiology Source Type: research

88 One-year outcomes of triple therapy and adherence with ESC guidelines in patients with AF undergoing PCI in a teaching hospital
Background/Introduction: Oral anticoagulation is the corner-stone for stroke prevention in Atrial Fibrillation (AF).Following Percutaneous Coronary Intervention (PCI) the risk of bleeding increase due to concomitant prescription of antiplatelet agents. The 2016 European Society of Cardiology( ESC) guidelines for non valvular AF provide clear recommendations for triple therapy  , Combination of two anti-platelet and oral anticoagulant in patients with underlying AF undergoing PCI, either electively or for acute coronary syndrome (ACS). The risk of such therapy is based on treatment duration and patient characteristics.
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research

103 How is our local AF management? The management of atrial fibrillation (af) in coventry and rugby clinical commissioning group (ccg), england compared to national data and nice (national institute for clinical excellence) 2014
Background: AF is the most common cardiac arrhythmia affecting 2% in the UK.AF carriers 5 fold risk of stroke, with increased stroke mortality, morbidity& longer hospital stay.CHADSVAs guides anti-coagulation ( ≥1 anti-coagulate)Risk factor modification reduces AF reoccurrenceNurse led clinics reduce AF related stroke risk, improve AF management, risk factor reduction whilst providing safe anticoagulation.
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research

Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital
Source: Europace - August 4, 2016 Category: Cardiology Authors: Pokorney, S. D., Steinberg, B. A. Tags: EDITORIALS Source Type: research

How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey
This European Heart Rhythm (EHRA) Scientific Initiatives Committee EP Wire Survey aimed at exploring the common practices in approaching patients with atrial fibrillation (AF) and informing them about their risk profiles and available therapies in Europe. In the majority of 53 responding centres, patients were seen by cardiologists (86.8%) or arrhythmologists (64.2%). First- and follow-up visits most commonly lasted 21–30 and 11–20 min (41.5 and 69.8% of centres, respectively). In most centres (80.2%) stroke and bleeding risk had the highest priority for discussion with AF patients; 50.9% of centres had a struc...
Source: Europace - February 26, 2015 Category: Cardiology Authors: Potpara, T. S., Pison, L., Larsen, T. B., Estner, H., Madrid, A., Blomstrom-Lundqvist, C., Conducted by the Scientific Initiatives Committee, and European Heart Rhythm Association, Conducted by the Scientific Initiatives Committee, and European Heart Rhyt Tags: EP WIRE Source Type: research